MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic

Sherin Ali Nawaito1,2, Dharmendra Dingar1,3, Pramod Sahadevan1,3

  • 1Montreal Heart Institute, Montréal, Québec, Canada.

Insights

Reduced MAPK-activated protein kinase-5 (MK5) in mice lessened cardiac hypertrophy and diastolic dysfunction following pressure overload. This suggests MK5 in cardiac fibroblasts plays a key role in myocardial remodeling and heart failure progression.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Protein Kinase Signaling

Background:

  • The physiological roles of MAPK-activated protein kinase-5 (MK5) are largely unknown.
  • MK5 is activated by p38 MAPK and atypical MAPKs ERK3/ERK4.
  • Understanding MK5's function is crucial for elucidating cardiac remodeling mechanisms.

Purpose of the Study:

  • To investigate the impact of MK5 haplodeficiency on cardiac function and myocardial remodeling.
  • To determine the role of MK5 in the response to chronic pressure overload.
  • To identify the cellular localization and function of MK5 in the heart.

Main Methods:

  • Utilized MK5 haplodeficient (MK5+/-) and wild-type (MK5+/+) mice.
  • Induced chronic pressure overload using Transverse Aortic Constriction (TAC).
  • Assessed cardiac function, hypertrophy markers, and collagen expression via molecular and physiological techniques.

Main Results:

  • MK5 haplodeficiency attenuated TAC-induced cardiac hypertrophy and collagen type 1 mRNA expression.
  • Reduced MK5 expression protected diastolic function and slowed the progression of hypertrophy post-TAC.
  • MK5 was localized to adult cardiac fibroblasts, not myocytes.

Conclusions:

  • Reduced MK5 expression in cardiac fibroblasts attenuates hypertrophy and restrictive filling patterns during pressure overload.
  • MK5 plays a significant role in cardiac fibroblast-mediated myocardial remodeling.
  • Targeting MK5 may offer a therapeutic strategy for heart failure with preserved ejection fraction.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551